GCG and Other metabolic disease: However, the recent implementations of GLP‐1/GIP receptor co‐agonists in the treatment of metabolic diseases (Jastreboff et al., 2022; Rosenstock et al., 2021) and GLP‐2/GIP receptor co‐agonists for the treatment of bone disorders (Gabe, Skov‐Jeppesen, et al., 2022) have made it important to study these presumably prominent effects of GIP.